ONO-4059_1351635-67-0_DataSheet_MedChemExpress

Product Name:

ONO-4059CAS No.:

1351635-67-0

Product Data Sheet

Cat. No.:

HY-18951MWt:

456.50Formula:

C25H24N6O3Purity :

>98%

Solubility:Mechanisms:

Biological Activity:

Pathways:Protein Tyrosine Kinase/RTK; Target:Btk

20 mg/ml in DMSO

g y ONO-4059 is a highly potent and selective Btk inhibitor with an IC50 in the sub-nM range.

IC50 value: sub-nM range [2]

Target: Btk in vitro: ONO-4059 is a selective, once-daily, oral inhibitor of BTK, which has been shown to play a role in the survival and proliferation of malignant B-cells. ONO-4059 shows a favourable safety

profile along with promising efficacy in this difficult-to-treat patient population. [1]in vivo: ONO-4059 has demonstrated anti-tumour activity in several pre-clinical models.[1] ONO-4059 potently and dose-dependently reverse clinical arthritis and prevented bone damage in the CIA References:

[1]. Simon Rule,A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With

Relapsed/Refractory B-Cell Lymphoma. November 15, 2013; Blood: 122 (21)[2]. Toshio Yoshizawa, et al. Development of a Bruton's Tyrosine Kinase (Btk) Inhibitor, ONO-4059:Efficacy in a Collagen Induced Arthritis (CIA) Model Indicates Potential Treatment for Rheumatoid p y p y p g model.[2]...

y g ()

Arthritis (RA). Washington, DC November 9-14, 2012.[3]. Yamamoto, et al. Preparation of purinone derivatives as selective Btk inhibitors. From PCT Int.

Appl. (2011), WO 2011152351 A1 20111208.Caution: Not fully tested. For research purposes only

Medchemexpress LLC

https://www.sodocs.net/doc/6214223939.html,

11 D e e r P a r k D r i v e , S u i t e 102D M o n m o u t h J u n c t i o n , N J 08852,U S A

E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m